These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 36614118)

  • 41. TDP-43 loss of function increases TFEB activity and blocks autophagosome-lysosome fusion.
    Xia Q; Wang H; Hao Z; Fu C; Hu Q; Gao F; Ren H; Chen D; Han J; Ying Z; Wang G
    EMBO J; 2016 Jan; 35(2):121-42. PubMed ID: 26702100
    [TBL] [Abstract][Full Text] [Related]  

  • 42. GPNMB ameliorates mutant TDP-43-induced motor neuron cell death.
    Nagahara Y; Shimazawa M; Ohuchi K; Ito J; Takahashi H; Tsuruma K; Kakita A; Hara H
    J Neurosci Res; 2017 Aug; 95(8):1647-1665. PubMed ID: 27935101
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Gain-of-function profilin 1 mutations linked to familial amyotrophic lateral sclerosis cause seed-dependent intracellular TDP-43 aggregation.
    Tanaka Y; Nonaka T; Suzuki G; Kametani F; Hasegawa M
    Hum Mol Genet; 2016 Apr; 25(7):1420-33. PubMed ID: 26908597
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [TDP-43 proteinopathies, toward understanding of the molecular pathogenesis].
    Hasegawa M; Nonaka T; Yamashita M; Kametani F; Arai T; Yoshida M; Hashizume Y; Tsuchiya K; Akiyama H
    Rinsho Shinkeigaku; 2009 Nov; 49(11):783-5. PubMed ID: 20030209
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Quantification of the Relative Contributions of Loss-of-function and Gain-of-function Mechanisms in TAR DNA-binding Protein 43 (TDP-43) Proteinopathies.
    Cascella R; Capitini C; Fani G; Dobson CM; Cecchi C; Chiti F
    J Biol Chem; 2016 Sep; 291(37):19437-48. PubMed ID: 27445339
    [TBL] [Abstract][Full Text] [Related]  

  • 46. TAR DNA-binding protein of 43 kDa (TDP-43) and amyotrophic lateral sclerosis (ALS): a promising therapeutic target.
    Ojaimi YA; Dangoumau A; Alarcan H; Hergesheimer R; Vourc'h P; Corcia P; Lanznaster D; Blasco H
    Expert Opin Ther Targets; 2022 Jun; 26(6):575-592. PubMed ID: 35652285
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Conjoint pathologic cascades mediated by ALS/FTLD-U linked RNA-binding proteins TDP-43 and FUS.
    Ito D; Suzuki N
    Neurology; 2011 Oct; 77(17):1636-43. PubMed ID: 21956718
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Amyotrophic lateral sclerosis and frontotemporal lobar degeneration: a spectrum of TDP-43 proteinopathies.
    Geser F; Lee VM; Trojanowski JQ
    Neuropathology; 2010 Apr; 30(2):103-12. PubMed ID: 20102519
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice.
    Igaz LM; Kwong LK; Lee EB; Chen-Plotkin A; Swanson E; Unger T; Malunda J; Xu Y; Winton MJ; Trojanowski JQ; Lee VM
    J Clin Invest; 2011 Feb; 121(2):726-38. PubMed ID: 21206091
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Disease animal models of TDP-43 proteinopathy and their pre-clinical applications.
    Liu YC; Chiang PM; Tsai KJ
    Int J Mol Sci; 2013 Oct; 14(10):20079-111. PubMed ID: 24113586
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Thioridazine reverts the phenotype in cellular and Drosophila models of amyotrophic lateral sclerosis by enhancing TDP-43 aggregate clearance.
    Cragnaz L; Spinelli G; De Conti L; Bureau EA; Brownlees J; Feiguin F; Romano V; Skoko N; Klima R; Kettleborough CA; Baralle FE; Baralle M
    Neurobiol Dis; 2021 Dec; 160():105515. PubMed ID: 34571136
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Therapeutic potential of novel Cell Division Cycle Kinase 7 inhibitors on TDP-43-related pathogenesis such as Frontotemporal Lobar Degeneration (FTLD) and amyotrophic lateral sclerosis (ALS).
    Vaca G; Martinez-Gonzalez L; Fernandez A; Rojas-Prats E; Porras G; Cuevas EP; Gil C; Martinez A; Martin-Requero Á
    J Neurochem; 2021 Feb; 156(3):379-390. PubMed ID: 32628315
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Co-deposition of SOD1, TDP-43 and p62 proteinopathies in ALS: evidence for multifaceted pathways underlying neurodegeneration.
    Trist BG; Fifita JA; Hogan A; Grima N; Smith B; Troakes C; Vance C; Shaw C; Al-Sarraj S; Blair IP; Double KL
    Acta Neuropathol Commun; 2022 Aug; 10(1):122. PubMed ID: 36008843
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antibody against TDP-43 phosphorylated at serine 375 suggests conformational differences of TDP-43 aggregates among FTLD-TDP subtypes.
    Neumann M; Frick P; Paron F; Kosten J; Buratti E; Mackenzie IR
    Acta Neuropathol; 2020 Nov; 140(5):645-658. PubMed ID: 32778941
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A robust TDP-43 knock-in mouse model of ALS.
    Huang SL; Wu LS; Lee M; Chang CW; Cheng WC; Fang YS; Chen YR; Cheng PL; Shen CJ
    Acta Neuropathol Commun; 2020 Jan; 8(1):3. PubMed ID: 31964415
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pathological and immunoblot analysis of phosphorylated TDP-43 in sporadic amyotrophic lateral sclerosis with pallido-nigro-luysian degeneration.
    Uchino A; Ogino M; Takahashi-Fujigasaki J; Oonuma S; Kanazawa N; Kajita S; Ichinoe M; Hasegawa M; Nishiyama K; Murayama S
    Neuropathology; 2018 Apr; 38(2):171-178. PubMed ID: 28906030
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Low molecular weight species of TDP-43 generated by abnormal splicing form inclusions in amyotrophic lateral sclerosis and result in motor neuron death.
    Xiao S; Sanelli T; Chiang H; Sun Y; Chakrabartty A; Keith J; Rogaeva E; Zinman L; Robertson J
    Acta Neuropathol; 2015 Jul; 130(1):49-61. PubMed ID: 25788357
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A90V TDP-43 variant results in the aberrant localization of TDP-43 in vitro.
    Winton MJ; Van Deerlin VM; Kwong LK; Yuan W; Wood EM; Yu CE; Schellenberg GD; Rademakers R; Caselli R; Karydas A; Trojanowski JQ; Miller BL; Lee VM
    FEBS Lett; 2008 Jun; 582(15):2252-6. PubMed ID: 18505686
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Aberrant assembly of RNA recognition motif 1 links to pathogenic conversion of TAR DNA-binding protein of 43 kDa (TDP-43).
    Shodai A; Morimura T; Ido A; Uchida T; Ayaki T; Takahashi R; Kitazawa S; Suzuki S; Shirouzu M; Kigawa T; Muto Y; Yokoyama S; Takahashi R; Kitahara R; Ito H; Fujiwara N; Urushitani M
    J Biol Chem; 2013 May; 288(21):14886-905. PubMed ID: 23558684
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations.
    Mackenzie IR; Bigio EH; Ince PG; Geser F; Neumann M; Cairns NJ; Kwong LK; Forman MS; Ravits J; Stewart H; Eisen A; McClusky L; Kretzschmar HA; Monoranu CM; Highley JR; Kirby J; Siddique T; Shaw PJ; Lee VM; Trojanowski JQ
    Ann Neurol; 2007 May; 61(5):427-34. PubMed ID: 17469116
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.